Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.